PhilippeSzaparyMDMSCE

Cardiology

Vice President, Immunology Clinical Development at Janssen, Pharmaceutical Companies of Johnson and Johnson. Preventative Cardiology

Join to view full profile

Dr. Szapary is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Szapary's full profile

Already have an account?

Office
3400 Civic Center Blvd
East Pavilion, 2nd Floor
Philadelphia, PA 19104
Phone+1 215-615-4949
Is this information wrong?

Education & Training

University of California (San Francisco)Residency, Internal Medicine, 1994 - 1997
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1994

Certifications & Licensure

PA State Medical License 1997 - 2024

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Safety and Effectiveness of Flaxseed for Reducing High Cholesterol Start of enrollment: 2003 Jan 01
Completed
Phase 2, Phase 3

Publications & Presentations

PubMed

3 citations
The Effect of Definitions and Cancer Prevalence on Diagnostic Yield Estimates of Bronchoscopy: A Simulation-based Analysis.
Anil Vachani, Fabien Maldonado, Balaji Laxmanan, Meijia Zhou, Iftekhar Kalsekar, Philippe Szapary, Lisa Dooley, Septimiu Murgu> ;Annals of the American Thoracic Society. 2023 Oct 1
Reply.
Anil Vachani, Meijia Zhou, Sudip Ghosh, Shumin Zhang, Philippe Szapary, Dheeraj Gaurav, Iftekhar Kalsekar> ;Journal of the American College of Radiology. 2024 Apr 1
4 citations
Stereotactic body radiation therapy and thermal ablation for treatment of NSCLC: A systematic literature review and meta-analysis.
Paul Laeseke, Calvin Ng, Nicole Ferko, Andrada Naghi, George W J Wright, Yuxin Zhang, Alyshia Laidlaw, Iftekhar Kalsekar, Balaji Laxmanan, Sudip K Ghosh, Meijia Zhou, ...> ;Lung Cancer. 2023 Aug 1
6 citations
Novel Image-Guided Flexible-Probe Transbronchial Microwave Ablation for Stage 1 Lung Cancer.
Michael A Pritchett, Janani S Reisenauer, Ryan Kern, David S Wilson, Erin E Meyers, Philippe O Szapary, Paul F Laeseke> ;Respiration; International Review of Thoracic Diseases. 2023 Jan 1
6 citations
Complications After Transthoracic Needle Biopsy of Pulmonary Nodules: A Population-Level Retrospective Cohort Analysis.
Anil Vachani, Meijia Zhou, Sudip Ghosh, Shumin Zhang, Philippe Szapary, Dheeraj Gaurav, Iftekhar Kalsekar> ;Journal of the American College of Radiology. 2022 Oct 1
53 citations
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
Omoniyi J. Adedokun, Zhenhua Xu, Colleen Marano, Christopher D. O'Brien, Philippe Szapary, Hongyan Zhang, Jewel Johanns, Rupert W. Leong, Tadakazu Hisamatsu, Gert Van ...> ;Clinical Gastroenterology and Hepatology. 2020 Sep 1
82 citations
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Bruce E. Sands, William J. Sandborn, Brian G. Feagan, Gary R. Lichtenstein, Hongyan Zhang, Richard Strauss, Philippe Szapary, Jewel Johanns, Julián Panés, Severine Ver...> ;Journal of Crohn's & Colitis. 2018 Nov 9
110 citations
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s Disease
Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul F. Pollack, Jean-Frederic Colombel, Douglas C. Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Sz...> ;Gastroenterology. 2018 Oct 1
15 citations
The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease.
Bruce E. Sands, C. Han, Christopher Gasink, Douglas Jacobstein, Philippe Szapary, Long-Long Gao, Yinghua Lang, Stephan R. Targan, William J. Sandborn, Brian G. Feagan> ;Journal of Crohn's & Colitis. 2018 Jul 30
152 citations
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Omoniyi J. Adedokun, Zhenhua Xu, Christopher Gasink, Douglas Jacobstein, Philippe Szapary, Jewel Johanns, Long Long Gao, Hugh M. Davis, Stephen B. Hanauer, Brian G. Fe...> ;Gastroenterology. 2018 May 1
16 citations
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
Robert Bissonnette, Francisco A. Kerdel, Luigi Naldi, Kim A. Papp, Claudia Galindo, Wayne Langholff, Kezhen L. Tang, Philippe Szapary, Steven Fakharzadeh, Bhaskar Sriv...> ;Journal of Drugs in Dermatology. 2017 Oct 1
19 citations
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis.
Robert Bissonnette, Francisco A. Kerdel, Luigi Naldi, Kim A. Papp, Claudia Galindo, Wayne Langholff, Kezhen L. Tang, Philippe Szapary, Steven Fakharzadeh, Bhaskar Sriv...> ;Journal of Drugs in Dermatology. 2017 Oct 1
10 citations
Challenges in longitudinal exposure-response modeling of data from complex study designs: a case study of modeling CDAI score for ustekinumab in patients with Crohn's ...
Chuanpu Hu, Omoniyi J. Adedokun, Yang Chen, Philippe Szapary, Christopher Gasink, Amarnath Sharma, Honghui Zhou> ;Journal of Pharmacokinetics and Pharmacodynamics. 2017 Jun 16
46 citations
HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program
Katherine Li, Conway C. Huang, Bruce Randazzo, Shu Li, Philippe Szapary, Mark Curran, Kim Campbell, Carrie Brodmerkel> ;The Journal of Investigative Dermatology. 2016 Dec 1
58 citations
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
Yanli Zhuang, Cesar Calderon, Stanley J. Marciniak, Esther Bouman-Thio, Philippe Szapary, Tong-Yuan Yang, Allen Schantz, Hugh M. Davis, Honghui Zhou, Zhenhua Xu> ;European Journal of Clinical Pharmacology. 2016 Aug 11
153 citations
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.
Ian Landells, Colleen Marano, Ming Chun Hsu, Shu Li, Yaowei Zhu, Lawrence F. Eichenfield, Peter H. Hoeger, Alan Menter, Amy S. Paller, Alain Taieb, Sandra Philipp, Phi...> ;Journal of the American Academy of Dermatology. 2015 Oct 1
231 citations
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Kenneth B. Gordon, Kristina Callis Duffin, Robert Bissonnette, Jörg C. Prinz, Y. Wasfi, Shu Li, Yaung Kaung Shen, Philippe Szapary, Bruce Randazzo, Kristian Reich> ;The New England Journal of Medicine. 2015 Jul 8
135 citations
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study throu...
Richard G. Langley, Mark Lebwohl, Gerald G. Krueger, Philippe Szapary, Y. Wasfi, Daphne Chan, Ming-Chun Hsu, Yin You, Yves Poulin, Neil J. Korman, Jörg C. Prinz, Krist...> ;The British Journal of Dermatology. 2015 May 1
17 citations
Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint
Chuanpu Hu, Philippe Szapary, Alan M. Mendelsohn, Honghui Zhou> ;Journal of Pharmacokinetics and Pharmacodynamics. 2014 Jul 20
213 citations
Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Howard Sofen, Stacy Smith, Robert Matheson, Craig L. Leonardi, Cesar Calderon, Carrie Brodmerkel, Katherine Li, Kim Campbell, Stanley J. Marciniak, Y. Wasfi, Y. Wang, ...> ;The Journal of Allergy and Clinical Immunology. 2014 Apr 1
142 citations
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
Alexa B. Kimball, Kim A. Papp, Y. Wasfi, Daphne Chan, Robert Bissonnette, Howard Sofen, N. Yeilding, Shu Li, Philippe Szapary, Kenneth B. Gordon> ;Journal of the European Academy of Dermatology and Venereology. 2013 Dec 1
46 citations
Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.
Carrie Brodmerkel, Eric Wadman, Richard G. Langley, Kim A. Papp, Marc Bourcier, Yves Poulin, Vincent T. Ho, Lyn Guenther, Rod Kunynetz, Simon Nigen, Ronald Vender, Nor...> ;Journal of Drugs in Dermatology. 2013 Oct 1
36 citations
Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis
Nehal N. Mehta, Katherine Li, Philippe Szapary, James G. Krueger, Carrie Brodmerkel> ;Journal of Translational Medicine. 2013 Aug 22
306 citations
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
Kim A. Papp, Christopher E.M. Griffiths, Kenneth B. Gordon, Mark Lebwohl, Philippe Szapary, Y. Wasfi, Daphne Chan, M-C Hsu, Ho, Pierre-Dominique Ghislain, Bruce Strobe...> ;The British Journal of Dermatology. 2013 Apr 1
66 citations
Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).
Xuejun Zhu, Min Zheng, Michael Song, Yaung-Kaung Shen, Daphne Chan, Philippe Szapary, Baoxi Wang, Lotus Investigators> ;Journal of Drugs in Dermatology. 2013 Feb 1
Join now to see all

Press Mentions

Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn’s Disease: An Integrated Analysis of Phase II/III Clinical Development ProgramsFebruary 9th, 2019
De Nouvelles Données De Phase 3 Montrent Qu'une Dose Unique De STELARAOctober 10th, 2018
New Phase 3 Data Show Single Dose of STELARAOctober 9th, 2018
Join now to see all